The US generics industry may finally have the leverage to pass a bill that would improve access to samples for testing after its savings were estimated at more than $3bn over 10 years.
The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act would allow generic companies to sue their brand counterparts...







